compound 2055269
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 20, 2018 (NCT03503630)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- compound 2055269
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03503630 | Phase 2 | Jul 20, 2018 | American University of Beirut, Merck KGaA, Phoenix Clinical Research Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| American University of Beirut | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Merck KGaA | For profit | 1 | 0 | 1 | 2018 |
| Phoenix Clinical Research Center | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1